Modality
Vaccine
MOA
Anti-Aβ
Target
TIGIT
Pathway
Epigenetic
BCC
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
~Oct 2017
→ ~Jan 2019
Phase 3
Apr 2019
→ Jul 2030
Phase 3Current
NCT05828103
2,043 pts·BCC
2024-03→2030-07·Terminated
NCT04511092
26 pts·BCC
2019-04→TBD·Active
NCT04653972
2,140 pts·BCC
2019-06→2029-01·Not yet recruiting
+1 more trial
6,225 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2029-01-142.8y awayPh3 Readout· BCC
2029-07-063.3y awayPh3 Readout· BCC
2030-07-054.3y awayPh3 Readout· BCC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Active
P3
Not yet…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2029-01-14 · 2.8y away
BCC
Ph3 Readout
2029-07-06 · 3.3y away
BCC
Ph3 Readout
2030-07-05 · 4.3y away
BCC
ActiveCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05828103 | Phase 3 | BCC | Terminated | 2043 | DAS28 |
| NCT04511092 | Phase 3 | BCC | Active | 26 | FEV1 |
| NCT04653972 | Phase 3 | BCC | Not yet recr... | 2140 | SeizFreq |
| NCT04690145 | Phase 3 | BCC | Completed | 2016 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |